Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC

NCT03603262 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SH-1028

Sponsor

Nanjing Sanhome Pharmaceutical, Co., Ltd.